Spots Global Cancer Trial Database for A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
Official Title: A Phase I, Multi-center, Open-label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given Weekly in Subjects With Solid Tumors
Study ID: NCT01358227
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Auckland, Auckland, , New Zealand
Waikato Hospital, Waikato, , New Zealand
Contact Details
Name: Mark McKeage, PhD, FRACP
Affiliation: University of Auckland, New Zealand
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
